European Archives - Page 518 of 1108 - European Medical Journal

The Safety of Medications During Pregnancy and Lactation in Patients with Inflammatory Rheumatic Diseases

The majority of inflammatory rheumatic diseases (IRDs) affect females more frequently and many have peaks in their childbearing age…

The Complete Management of Psoriatic Disease in a COVID World

In this opening video, which includes a patient’s perspective of living with psoriasis, Professor Diamant Thaçi (Chair) begins with his opening remarks and introductions, and gives an overview of the agenda.

Is Brain Stimulation the Answer to Severe Mental Illnesses?

MERGING artificial intelligence with targeted electrical brain stimulation has been found to improve certain human brain functions…

Shedding New Light on Alzheimer’s Disease Progression

PIONEERING researchers have used human data to assess the speed at which different processes lead to the development of Alzheimer’s disease…

Link Found Between Fast-Food Restaurants and Type 2 Diabetes

An insightful study conducted in the USA shared the problematic link between fast-food restaurants and Type 2 diabetes (T2D)…

Is Dapagliflozin Effective in Reducing Albuminuria in Diabetes?

Further analysis demonstrated that dapagliflozin increased the likelihood of regression in patients with a UACR of 300 or more in 3,860 patients…

An Incoming Epidemic

Dr. Fasiha Kanwal explores her work towards fighting non-alcoholic steatohepatitis (NASH), underlining the importance of changing lifestyles.

EMJ Hematology 9 [Supplement 6] 2021 Feature Image

EMJ Hematology 9 [Supplement 6] 2021

This review provides a summary of the research presented by a panel of three experts at the virtual webcast symposium conference hosted by PeerVoice on 20th May 2021.

EMJ Oncology 9 [Supplement 8] 2021 Feature Image

Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?

Although approximately 60% of patients with diffuse large B-cell lymphoma (DLBCL) can be cured, the remaining 40% have relapsed or refractory disease (R/R DLBCL). Substantial unmet need remains for effective, safe therapies for these patients. Novel targeted approaches to the treatment of R/R DLBCL include CD19-directed antibodies, antibody–drug conjugates, bispecific monoclonal antibodies, and anti-CD-19 chimeric antigen receptor (CAR) T-cell therapies.

Eleven Myths on Nail Melanoma

A number of misconceptions prevail in nail melanoma. This short essay tries to clarify some of these issues.